The Manufacturers Life Insurance Company Acquires New Holdings in IQVIA Holdings Inc. $IQV

Posted by George Bondi on Aug 26th, 2026

The Manufacturers Life Insurance Company bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 628,936 shares of the medical research company’s stock, valued at approximately $121,523,000. The Manufacturers Life Insurance Company owned 0.38% of IQVIA at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Trajan Wealth LLC purchased a new position in shares of IQVIA during the 2nd quarter valued at $35,266,000. Peak Asset Management LLC purchased a new position in IQVIA during the second quarter worth about $474,000. L2 Asset Management LLC bought a new position in IQVIA in the 2nd quarter worth about $1,942,000. Vega Investment Solutions purchased a new stake in shares of IQVIA in the 2nd quarter valued at about $709,000. Finally, SaddleRock Capital Management LLC purchased a new position in shares of IQVIA during the second quarter worth about $9,551,000. 89.62% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on IQV shares. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Royal Bank Of Canada lifted their price objective on shares of IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on IQVIA in a research report on Thursday, July 9th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Finally, Barclays reissued an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

Read Our Latest Stock Report on IQVIA

IQVIA Stock Performance

NYSE IQV opened at $259.97 on Wednesday. The firm has a market cap of $42.79 billion, a price-to-earnings ratio of 32.25, a PEG ratio of 2.21 and a beta of 1.18. The company has a 50-day simple moving average of $216.59 and a two-hundred day simple moving average of $188.02. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $261.88.

IQVIA (NYSE:IQV – Get Free Report) last released its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter in the previous year, the company posted $2.81 EPS. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA declared that its board has approved a share repurchase plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In other news, insider Bhavik Patel sold 1,855 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This represents a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider W Richard Staub sold 5,500 shares of the stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. The trade was a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 12,913 shares of company stock worth $3,098,793. Company insiders own 1.70% of the company’s stock.

About IQVIA

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.